BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1973358)

  • 1. The relationship between multidrug resistance and tumor necrosis factor resistance in an EL4 cell line model.
    Ujhazy P; Chen YF; Fredericks W; Ho RL; Mihich E; Baker RM; Ehrke MJ
    Cancer Commun; 1990; 2(5):181-8. PubMed ID: 1973358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype.
    Safrit JT; Berek JS; Bonavida B
    Gynecol Oncol; 1993 Feb; 48(2):214-20. PubMed ID: 8428693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression.
    Zyad A; Bénard J; Tursz T; Clarke R; Chouaib S
    Cancer Res; 1994 Feb; 54(3):825-31. PubMed ID: 7905787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
    Baas F; Jongsma AP; Broxterman HJ; Arceci RJ; Housman D; Scheffer GL; Riethorst A; van Groenigen M; Nieuwint AW; Joenje H
    Cancer Res; 1990 Sep; 50(17):5392-8. PubMed ID: 1974823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha.
    Licht T; Lübbert M; Martens C; Bross KJ; Fiebig HH; Mertelsmann R; Herrmann F
    Cytokines Mol Ther; 1995 Jun; 1(2):123-32. PubMed ID: 9384669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression.
    Slapak CA; Daniel JC; Levy SB
    Cancer Res; 1990 Dec; 50(24):7895-901. PubMed ID: 1979251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
    Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN
    Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Synergistic effect of bromocriptine combining tumor necrosis factor-alpha on reversing multidrug resistance in a nude mouse model of liver neoplasm].
    Ding L; Chen XP; Zhang ZW; Wang H; Cao B; Wang ZH; Li CL
    Zhonghua Wai Ke Za Zhi; 2005 Oct; 43(19):1248-53. PubMed ID: 16271222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
    Gutierrez PL; Wilder PJ; Biswal N
    Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined activity of interleukin-1 alpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects.
    Borsellino N; Crescimanno M; Flandina C; Flugy A; D'Alessandro N
    Anticancer Res; 1994; 14(6B):2643-8. PubMed ID: 7872695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
    Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
    Hill AB; Beck WT; Trent JM
    Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is associated with multidrug resistance.
    Ho SB; Yan PS; Dahiya R; Neuschwander-Tetri BA; Basbaum C; Kim YS
    J Cell Physiol; 1994 Aug; 160(2):213-26. PubMed ID: 7913708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210.
    Volm M; Mattern J; Pommerenke EW
    Anticancer Res; 1991; 11(2):579-85. PubMed ID: 1676579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
    Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
    Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins.
    Morimoto H; Yonehara S; Bonavida B
    Cancer Res; 1993 Jun; 53(11):2591-6. PubMed ID: 7684321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
    Wu L; Smythe AM; Stinson SF; Mullendore LA; Monks A; Scudiero DA; Paull KD; Koutsoukos AD; Rubinstein LV; Boyd MR
    Cancer Res; 1992 Jun; 52(11):3029-34. PubMed ID: 1350507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.